凯赛生物(688065) - 2024 Q1 - 季度财报

Revenue and Profit Growth - Revenue for Q1 2024 reached 684,521,536.95 RMB, a year-on-year increase of 35.43%[4] - Net profit attributable to shareholders of the listed company was 105,258,699.94 RMB, up 83.25% year-on-year[4] - Total operating revenue for Q1 2024 reached RMB 684.52 million, a 35.4% increase compared to RMB 505.45 million in Q1 2023[18] - Net profit attributable to parent company shareholders in Q1 2024 was RMB 105.26 million, up 83.3% from RMB 57.44 million in Q1 2023[19] - Basic earnings per share (EPS) for Q1 2024 were RMB 0.18, an 80% increase from RMB 0.10 in Q1 2023[20] - Basic and diluted earnings per share both increased by 80.00% to 0.18 RMB per share[8] R&D Investment - R&D investment totaled 44,784,258.67 RMB, a decrease of 9.89% year-on-year[4] - R&D investment as a percentage of revenue decreased by 3.29 percentage points to 6.54%[5] - R&D expenses in Q1 2024 decreased by 9.9% to RMB 44.78 million from RMB 49.70 million in Q1 2023[18] Cash Flow and Operating Activities - Net cash flow from operating activities surged to 215,276,527.96 RMB, a 171.65% increase compared to the same period last year[4] - Cash flow from operating activities in Q1 2024 was RMB 649.16 million, a 33.8% increase compared to RMB 485.11 million in Q1 2023[21] - Operating cash flow net amount: 215,276,527.96, an increase of 79,246,727.84 compared to the previous period[22] - Cash paid for goods and services in Q1 2024 was RMB 366.11 million, a 21.7% increase compared to RMB 300.90 million in Q1 2023[21] Assets and Liabilities - Total assets at the end of the reporting period were 18,617,743,763.23 RMB, a slight decrease of 1.14%[5] - Total assets decreased from RMB 18,833,372,759.88 to RMB 18,617,743,763.23, a decrease of approximately 1.15%[17] - Current assets decreased from RMB 7,570,668,208.85 to RMB 7,151,482,571.06, a decrease of approximately 5.53%[15] - Non-current assets increased from RMB 11,262,704,551.03 to RMB 11,466,261,192.17, an increase of approximately 1.81%[16] - Total liabilities decreased from RMB 4,060,262,557.16 to RMB 3,753,843,629.70, a decrease of approximately 7.55%[17] - Current liabilities decreased from RMB 3,409,752,675.79 to RMB 2,753,663,906.38, a decrease of approximately 19.24%[16] - Non-current liabilities increased from RMB 650,509,881.37 to RMB 1,000,179,723.32, an increase of approximately 53.76%[17] - Shareholders' equity increased from RMB 14,773,110,202.72 to RMB 14,863,900,133.53, an increase of approximately 0.61%[17] Cash and Cash Equivalents - Cash and cash equivalents decreased from RMB 5,390,218,174.98 to RMB 4,987,762,122.15, a decrease of approximately 7.47%[15] - Net increase in cash and cash equivalents: -218,561,556.52, an improvement of 156,098,219.90 compared to the previous period[22] - Ending cash and cash equivalents balance: 4,795,218,006.40, a decrease of 1,055,199,460.73 compared to the previous period[22] Accounts Receivable and Inventory - Accounts receivable increased from RMB 243,255,891.12 to RMB 291,690,168.89, an increase of approximately 19.91%[15] - Inventory decreased from RMB 1,466,355,603.97 to RMB 1,374,593,313.28, a decrease of approximately 6.26%[15] Operating Costs and Expenses - Operating costs for Q1 2024 were RMB 559.74 million, a 26.7% increase compared to RMB 441.82 million in Q1 2023[18] - Sales expenses in Q1 2024 were RMB 12.29 million, a slight 1.9% increase from RMB 12.07 million in Q1 2023[18] - Management expenses decreased by 33.6% to RMB 43.24 million in Q1 2024 from RMB 65.18 million in Q1 2023[18] Investment and Financing Activities - Cash outflow for investment activities: 463,229,410.48, a decrease of 23,865,493.07 compared to the previous period[22] - Cash inflow from financing activities: 728,258,447.26, an increase of 430,958,447.26 compared to the previous period[22] - Net cash flow from financing activities: 28,319,643.87, a decrease of 125,491,078.35 compared to the previous period[22] Government Subsidies and Non-Recurring Gains - Government subsidies contributed 3,143,696.20 RMB to non-recurring gains[6] Shareholder Information - The top shareholder, Cathay Industrial Biotech Ltd., holds 28.32% of the company's shares[9] Comprehensive Income - Total comprehensive income for Q1 2024 was RMB 104.78 million, a 49.2% increase from RMB 70.23 million in Q1 2023[19] Accounting Standards - The company did not apply new accounting standards or interpretations in 2024[23] Market Demand and Product Expansion - The company's long-chain dicarboxylic acid sales and revenue increased significantly due to market demand recovery and new product expansion[8]